Development Research Program

孢子发育研究计划的目标是促进针对孢子转译黑色素瘤研究的新想法。孢子指南要求勤奋努力，通过提供正式的发展研究计划(DRP)来确定和资助试点项目，该计划将突出和支持新的研究努力，无论是一个或多个孢子内的科学家之间的合作，还是与孢子环境外的新科学家的合作，最终可能会降低发病率和发病率或提高黑色素瘤患者的存活率。实验室和临床研究项目都有资格获得资助，尽管这些项目必须以翻译目标为目标。NCI孢子预算的一部分(每年75,000美元)将每年分配给这些试点项目。加上M.D.安德森提供的配套资金(DRP和CDP每年各增加100,000美元)作为其对孢子的机构承诺的一部分，我们每年有175,000美元用于支持黑色素瘤的DRP。 在这4.5年里，孢子DRP已经支持了36个DRP黑色素瘤奖项。根据基金的不同，每年提供的奖励数目各不相同，这在很大程度上取决于以前资助的项目是否获得第二年供资的批准而产生的实际余额。我们的结果表明，孢子基金极大地增强和扩大了新项目的开发潜力，在这些项目中，项目可以转移到完整的孢子项目，或者竞争其他资金。我们已经实现了DRP的具体目标。到目前为止，资助的36个不同项目代表了来自M.D.安德森以及我们邻近机构的16个不同部门和部门的研究人员，包括加尔维斯顿的德克萨斯大学医学部。虽然我们的孢子还很年轻，而且刚刚获奖者已经看到了他们资助的结果，但这一努力已经取得了重大进展，包括4名DRP调查人员现在被列为完整项目的联合负责人，提交和/或发表了43篇手稿。已提交21项赠款，其中14项已收到资金，4项目前正在审查中。这些进展证明了孢子发育研究计划对整个黑色素瘤研究的重要性和成功，以及我们在M.D.安德森所做的当地努力。我们的计划是通过征求建议书的方式继续这一计划，每个建议书最高可达5万美元，并提供初步的 分期付款为25,000美元，如果初步目标实现，并且执行委员会和实验室委员会可以证明进展和需要是合理的，则再支付25,000美元。

The goal of the SPORE Development Research Program is to promote new ideas directed toward the SPORE translational melanoma research. SPORE guidelines mandate diligent efforts to identify and fund pilot projects by providing a formal Developmental Research Program (DRP) that will highlight and support new research endeavors, whether collaborative among scientists within one or more SPOREs, or with new scientists outside the SPORE environment, that may eventually reduce the incidence and morbidity or increase the survival of melanoma patients. Both laboratory and clinical research projects are eligible for funding although the projects must aim toward a translational goal. A portion of the NCI SPORE budget ($75,000 per year) will be allocated annually to support these pilot projects. With matching funds (an additional $100,000 per year for each the DRP and CDP) provided by the M.D. Anderson as part of its nstitutional commitment to the SPORE, we have had $175,000 each year to support the DRP in Melanoma. Over these 4.5 years the SPORE DRP has supported 36 DRP in melanoma awards. The number of awards offered each year varied, depending on funds, based in large part on the actual balance due to whether previously funded projects were approved for a second year of funding. Our results, show that SPORE funds greatly enhanced and expanded the potential for development of new projects in which preliminary data was required before the project could move to a full SPORE project, or compete for other funding. We have achieved the specific objectives of the DRP. The 36 different projects funded to date represent investigators from 16 different Departments and Divisions at M.D. Anderson as well as at our neighboring institutions, including the U.T. Medical Branch at Galveston. Although our SPORE is young, and the early awardees just now are seeing the results of their funding, this effort has led to significant progress including 4 DRP investigators now included as Co-Leaders of full projects, 43 manuscripts submitted, and/or published. Twenty-one grants were submitted with 14 of these receiving funding and 4 under review at this time. These advances are evidence of the importance and success of the SPORE Developmental Research Program to melanoma research overall as well as to our local efforts at M.D. Anderson. Our plans are to continue this program by solicitation of proposals for a maximum of $50,000 each, and provide the initial installment of $25,000 followed by an additional $25,000 if the initial goals are met and the progress and need can be justified to the Executive and lAB committees.